Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 24;9(4):302.
doi: 10.3390/vaccines9040302.

COVID-19 Vaccine Hesitancy among French People Living with HIV

Alexandre Vallée  1 , Erwan Fourn  2 , Catherine Majerholc  2 , Pauline Touche  1 , David Zucman  2
Affiliations

COVID-19 Vaccine Hesitancy among French People Living with HIV

Alexandre Vallée et al. Vaccines (Basel). .

Abstract

People living with HIV are a high-risk population concerning the coronavirus 19 (COVID-19) infection, with a poorer prognosis. It is important to achieve high COVID-19 vaccination coverage rates in this group as soon as possible. This project used self-reporting to assess vaccine hesitancy and acceptance among people living with HIV towards the novel COVID-19 vaccine. Sixty-eight (28.7%) participants among the 237 declared their hesitancy to be vaccinated against COVID-19. Participants who expressed concerns about their health (p < 0.001), the requirement of mandatory COVID-19 vaccination (p = 0.017), and their chronic disease status (p = 0.026) were independently associated with the acceptance of vaccination. Conversely, participants presenting general vaccine refusal (p < 0.001), concerns about the serious side effects of COVID-19 vaccines (p < 0.001), and those already thinking having an immune status to COVID-19 (p = 0.008) were independently associated with COVID-19 vaccine hesitancy. Our results suggest that vaccine strategy would be more successful in France with a communication strategy emphasizing the collective benefits of herd immunity in the population living with HIV and reassuring patients with chronic diseases about the safety of the proposed vaccines.

Keywords: COVID-19; COVID-19 vaccine; HIV; vaccine hesitancy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Draft Landscape and Tracker of COVID-19 Candidate Vaccines. [(accessed on 12 February 2021)]; Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand....
    1. Anderson R.M., Vegvari C., Truscott J., Collyer B.S. Challenges in Creating Herd Immunity to SARS-CoV-2 Infection by Mass Vaccination. The Lancet. 2020;396:1614–1616. doi: 10.1016/S0140-6736(20)32318-7. - DOI - PMC - PubMed
    1. Carrat F., De Lamballerie X., Rahib D., Blanche H., Lapidus N., Artaud F., Kab S., Renuy A., De Edelenyi F.S., Meyer L., et al. Seroprevalence of SARS-CoV-2 among Adults in Three Regions of France Following the Lockdown and Associated Risk Factors: A Multicohort Study. medRxiv. 2020 doi: 10.1101/2020.09.16.20195693. - DOI

LinkOut - more resources